In terms of ATEs in patients receiving anti-VEGF agents, our study reported slightly higher incidence than that of the Singapore study population but remarkably lower incidence than that of the United States study population, which revealed a cumulative risk of 7.2% for stroke and 6.1% for MI [26, 27]. Here, VEGFA is linked to Stroke.